. Author manuscript; available in PMC: 2006 Mar 28.

Published in final edited form as: J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):31–36. doi: 10.1097/00126334-200501010-00006

TABLE 2.

Prediction of HAD by Markers of Glucose Metabolism

Marker of Glucose Metabolism	Research Diagnosis			Unadjusted Odds Ratio (95% CI) P Value	Adjusted^* Odds Ratio (95% CI) P Value	Further Adjusted^† Odds Ratio (95% CI) P Value
Marker of Glucose Metabolism	Normal	MCMD	HAD	Unadjusted Odds Ratio (95% CI) P Value	Adjusted^* Odds Ratio (95% CI) P Value	Further Adjusted^† Odds Ratio (95% CI) P Value
Diabetes mellitus, n (%)	4/8 (4.55%)	5/72 (6.94%)	8/39 (20.51%)	4.33 (1.55–12.10)	5.43 (1.66–17.70)	5.73 (1.52–21.62)
				<0.01	<0.01	<0.01
^‡Glucose (mg/dL), mean ± SD	88.35 ± 12.86	93.00 ± 10.74	95.19 ± 10.80	1.04 (0.99–1.08)	1.03 (0.98–1.08)	1.03 (0.98–1.08)
n	55	45	16	=0.14	=0.22	=0.29
^§Insulin resistance, mean ± SD	2.24 ± 1.40		2.80 ± 1.45	1.541 (0.63–4.06)
n	12		3	=0.34

The outcome tested was HAD vs. any other diagnostic category. Normal category includes participants categorized as NP abnormal. For insulin resistance, exact logistic regression was used due to the small sample size.

Adjusted for demographic and disease severity variables: age, education, ethnicity, on ARV with PI, duration of infection, and CD4 count.

^†

Additionally adjusted for the following cardiovascular risk variables: hypercholesterolemia, hypertension, and pack-years of smoking.

^‡

Participants without diabetes mellitus for whom fasting glucose levels were available.

^§

Participants without diabetes mellitus for whom insulin resistance could be estimated via HOMA. Normal and MCMD grouped together.